胆汁酸核受体和脂肪因子在非酒精性脂肪性肝病发病中的作用*

doi:10.3969/j.issn.1672-5069.2014.01.031

摘要/Abstract

摘要： 非酒精性脂肪性肝病是世界范围内最常见的一种慢性肝病,胰岛素抵抗是其主要的发病原因之一,但其具体发病机制尚不十分明确。近年研究发现影响胆汁酸核受体的措施具有改善胰岛素抵抗和抗肝纤维化等作用。脂肪细胞分泌的多种脂肪因子在非酒精性脂肪性肝病的发生、发展中也起着重要的作用。另外,研究还发现胆汁酸核受体的变化可影响脂肪因子的分泌。

关键词: 非酒精性脂肪性肝病, 脂肪因子, 胆汁酸核受体

Abstract: Non-alcoholic fatty liver disease（NAFLD）is the most common chronic liver disease worldwild. Insulin resistance is among the major causes of NAFLD,but its specific pathogenesis is still unclear. Recent findings show that bile acid nuclear receptors improve insulin resistance and liver fibrosis. Furthernore,a variety of adipokines secreted by fat cells play an important roles in the onset and progression of NAFLD. In addition,studies also show that bile acid nuclear receptors can affect the secretion of adipokines.

Key words: Nonalcoholic fatty liver disease, Adipokines, Bile acid nuclear receptor

辛小敏综述, 朱薇, 张亚历审校. 胆汁酸核受体和脂肪因子在非酒精性脂肪性肝病发病中的作用^*[J]. 实用肝脏病杂志, 2014, 17(1): 95-98.

Xin Xiaomin, Zhu Wei, Zhang Yali. Bile acid nuclear receptors and adipokines in the pathogenesis of non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 95-98.

参考文献

[1] 魏珏,叶丽静,邱德凯,等. 胆汁酸核受体FXR在非酒精性脂肪性肝病中的作用. 胃肠病学,2010,15（1）：21-24.
[2] Gariani K,Philippe J,Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance：from bench to bedside. Diabetes Metab,2013,39（1）：16-26.
[3] Sinal CJ,Tohkin M,Miyata M,et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell,2000,102（6）：731-744.
[4] Claudel T,Inoue Y,Barbier O,et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology,2003,125（2）：544-555.
[5] Yamagata K,Daitoku H,Shimamoto Y,et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem,2004,279（22）：23158-23165.
[6] Wang YD,Chen WD,Wang M,et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response. Hepatology,2008,48（5）：1632-1643.
[7] Zhang S,Wang J,Liu Q,et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol,2009,51（2）：380-388.
[8] Arita Y,Kihara S,Ouchi N,et al. Paradoxical decrease of an adipose-specific protein,adiponectin,in obesitys. Biochem Biophys Res Commun,1999,257（1）：79-83.
[9] Cnop M,Havel PJ,Utzschneider K M,et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins：evidence for independent roles of age and sex. Diabetologia,2003,46（4）：459-469.
[10] Polyzos SA,Kountouras J,Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. Hippokratia,2009, 13（2）：127-128.
[11] Buechler C,Wanninger J,Neumeier M. Adiponectin,a key adipokine in obesity related liver diseases. World J Gastroenterol,2011,17（23）：2801-2811.
[12] Polyzos SA,Toulis KA,Goulis DG,et al. Serum total adiponectin in nonalcoholic fatty liver disease：a systematic review and meta-analysis. Metabolism,2011,60（3）：313-326.
[13] Cohen B,Novick D,Rubinstein M.Modulation of insulin activities by leptin. Science,1996,274（5290）：1185-1188.
[14] Ikejima K,Honda H,Yoshikawa M,et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology,2001,34（2）：288-297.
[15] Canbakan B,Tahan V,Balci H,et al. Leptin in nonalcoholic fatty liver disease. Ann Hepatol,2008,7（3）：249-254.
[16] Javor ED,Ghany MG,Cochran EK,et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology,2005,41（4）：753-760.
[17] Reitman ML. Leptin in the liver： a toxic or beneficial mix?. Cell Metab,2012,16（1）：1-2.
[18] Ghosh S,Singh AK,Aruna B,et al. The genomic organization of mouse resistin reveals major differences from the human resistin： functional implications. Gene,2003,305（1）：27-34.
[19] Muse ED,Obici S,Bhanot S,et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest,2004,114（2）： 232-239.
[20] Singhal NS,Patel RT,Qi Y,et al. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab,2008,295（2）：331-338.
[21] Fu Y,Luo L,Luo N,et al. Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutr Metab （Lond）,2006,3（1）：28-37.
[22] 杨云鹏,管小琴,祁明美,等. 抵抗素对NAFLD肝纤维化的影响及可能的体内外机制. 动物学研究,2012,33（4）：367-372.
[23] Zhou L,Yu X,Meng Q,et al. Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway. Hepatology,2013,57（4）：1384-1393.
[24] Sheng CH,Di J,Jin Y,et al. Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine,2008,33（2）：135-143.
[25] Pagano C,Soardo G,Pilon C,et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab,2006,91（3）：1081-1086.
[26] Perseghin G,Lattuada G,De Cobelli F,et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab,2006, 91（12）：5122-5125.
[27] Szalowska E,Elferink MG,Hoek A,et al. Resistin is more abundant in liver than adipose tissue and is not up-regulated by lipopolysaccharide. J Clin Endocrinol Metab,2009,94（8）：3051-3057.
[28] Rizzo G,Disante M,Mencarelli A,et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol,2006,70（4）：1164-1173.
[29] Abdelkarim M,Caron S,Duhem C,et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem, 2010,285（47）：36759-36767.
[30] Liang CP,Tall AR. Transcriptional profiling reveals global defects in energy metabolism,lipoprotein,and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem,2001,276（52）：49066-49076.
[31] Vanpatten S,Karkanias GB,Rossetti L,et al. Intracerebroventricular leptin regulates hepatic cholesterol metabolism. Biochem J,2004,379（2）：229-233.

胆汁酸核受体和脂肪因子在非酒精性脂肪性肝病发病中的作用^*

Bile acid nuclear receptors and adipokines in the pathogenesis of non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[10]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[11]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[12]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[13]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[14]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[15]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.